Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1999 1
2001 1
2002 2
2003 1
2004 3
2009 1
2011 1
2014 1
2017 2
2018 4
2019 1
2020 3
2021 3
2022 4
2023 6
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

32 results

Results by year

Filters applied: . Clear all
Page 1
Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial.
Shitara K, Özgüroğlu M, Bang YJ, Di Bartolomeo M, Mandalà M, Ryu MH, Fornaro L, Olesiński T, Caglevic C, Chung HC, Muro K, Goekkurt E, Mansoor W, McDermott RS, Shacham-Shmueli E, Chen X, Mayo C, Kang SP, Ohtsu A, Fuchs CS; KEYNOTE-061 investigators. Shitara K, et al. Lancet. 2018 Jul 14;392(10142):123-133. doi: 10.1016/S0140-6736(18)31257-1. Epub 2018 Jun 4. Lancet. 2018. PMID: 29880231 Clinical Trial.
The molecular characteristics of high-grade gastroenteropancreatic neuroendocrine neoplasms.
Venizelos A, Elvebakken H, Perren A, Nikolaienko O, Deng W, Lothe IMB, Couvelard A, Hjortland GO, Sundlöv A, Svensson J, Garresori H, Kersten C, Hofsli E, Detlefsen S, Krogh M, Sorbye H, Knappskog S. Venizelos A, et al. Among authors: hjortland go. Endocr Relat Cancer. 2021 Nov 11;29(1):1-14. doi: 10.1530/ERC-21-0152. Endocr Relat Cancer. 2021. PMID: 34647903 Free PMC article.
A national precision cancer medicine implementation initiative for Norway.
Taskén K, Russnes HEG, Aas E, Bjørge L, Blix ES; CONNECT Public–Private Partnership Consortium; Enerly E, Fagereng GL, Flobak Å, Gilje B, Gjertsen BT, Guren TK, Heix J, Hovig E, Hovland R; InPreD-Norway and National Molecular Tumor Board Consortium; IMPRESS-Norway Consortium; Lønning PE, Meza-Zepeda LA, Mæhle PM, Nilsen HL, Thoresen SØ, Widerberg K, Smeland S, Helland Å. Taskén K, et al. Nat Med. 2022 May;28(5):885-887. doi: 10.1038/s41591-022-01777-4. Nat Med. 2022. PMID: 35513529 No abstract available.
Oncological outcomes of standard versus prolonged time to surgery after neoadjuvant chemoradiotherapy for oesophageal cancer in the multicentre, randomised, controlled NeoRes II trial.
Nilsson K, Klevebro F, Sunde B, Rouvelas I, Lindblad M, Szabo E, Halldestam I, Smedh U, Wallner B, Johansson J, Johnsen G, Aahlin EK, Johannessen HO, Alexandersson von Döbeln G, Hjortland GO, Wang N, Shang Y, Borg D, Quaas A, Bartella I, Bruns C, Schröder W, Nilsson M. Nilsson K, et al. Among authors: hjortland go. Ann Oncol. 2023 Nov;34(11):1015-1024. doi: 10.1016/j.annonc.2023.08.010. Epub 2023 Aug 30. Ann Oncol. 2023. PMID: 37657554 Free article. Clinical Trial.
Germline pathogenic variants in patients with high-grade gastroenteropancreatic neuroendocrine neoplasms.
Venizelos A, Sorbye H, Elvebakken H, Perren A, Lothe IMB, Couvelard A, Hjortland GO, Sundlöv A, Svensson J, Garresori H, Kersten C, Hofsli E, Detlefsen S, Vestermark LW, Ladekarl M, Tabaksblat EM, Knappskog S. Venizelos A, et al. Among authors: hjortland go. Endocr Relat Cancer. 2023 Aug 23;30(10):e230057. doi: 10.1530/ERC-23-0057. Print 2023 Oct 1. Endocr Relat Cancer. 2023. PMID: 37410378 Free article.
Improving public cancer care by implementing precision medicine in Norway: IMPRESS-Norway.
Helland Å, Russnes HG, Fagereng GL, Al-Shibli K, Andersson Y, Berg T, Bjørge L, Blix E, Bjerkehagen B, Brabrand S, Cameron MG, Dalhaug A, Dietzel D, Dønnem T, Enerly E, Flobak Å, Fluge S, Gilje B, Gjertsen BT, Grønberg BH, Grønås K, Guren T, Hamre H, Haug Å, Heinrich D, Hjortland GO, Hovig E, Hovland R, Iversen AC, Janssen E, Kyte JA, von der Lippe Gythfeldt H, Lothe R, Lund JÅ, Meza-Zepeda L, Munthe-Kaas MC, Nguyen OTD, Niehusmann P, Nilsen H, Puco K, Ree AH, Riste TB, Semb K, Steinskog ESS, Stensvold A, Suhrke P, Tennøe Ø, Tjønnfjord GE, Vassbotn LJ, Aas E, Aasebø K, Tasken K, Smeland S. Helland Å, et al. Among authors: hjortland go. J Transl Med. 2022 May 14;20(1):225. doi: 10.1186/s12967-022-03432-5. J Transl Med. 2022. PMID: 35568909 Free PMC article. Clinical Trial.
Phase II study of everolimus and temozolomide as first-line treatment in metastatic high-grade gastroenteropancreatic neuroendocrine neoplasms.
Morken S, Langer SW, Sundlöv A, Vestermark LW, Ladekarl M, Hjortland GO, Svensson JB, Tabaksblat EM, Haslerud TM, Assmus J, Detlefsen S, Couvelard A, Perren A, Sorbye H. Morken S, et al. Among authors: hjortland go. Br J Cancer. 2023 Dec;129(12):1930-1939. doi: 10.1038/s41416-023-02462-0. Epub 2023 Oct 23. Br J Cancer. 2023. PMID: 37872405 Free PMC article. Clinical Trial.
PD-L1 expression in gastroenteropancreatic neuroendocrine neoplasms grade 3.
Ali AS, Langer SW, Federspiel B, Hjortland GO, Grønbæk H, Ladekarl M, Welin S, Weber Vestermark L, Arola J, Osterlund P, Knigge U, Sørbye H, Micke P, Grimelius L, Grönberg M, Tiensuu Janson E. Ali AS, et al. Among authors: hjortland go. PLoS One. 2020 Dec 14;15(12):e0243900. doi: 10.1371/journal.pone.0243900. eCollection 2020. PLoS One. 2020. PMID: 33315908 Free PMC article.
Mutation Spectrum in Liquid Versus Solid Biopsies From Patients With Advanced Gastroenteropancreatic Neuroendocrine Carcinoma.
Knappskog S, Grob T, Venizelos A, Amstutz U, Hjortland GO, Lothe IM, Kersten C, Hofsli E, Sundlöv A, Elvebakken H, Garresori H, Couvelard A, Svensson J, Sorbye H, Perren A. Knappskog S, et al. Among authors: hjortland go. JCO Precis Oncol. 2023 Feb;7:e2200336. doi: 10.1200/PO.22.00336. JCO Precis Oncol. 2023. PMID: 36753687 Free PMC article.
32 results